The biosimilar void: why Europe’s next decade of drug savings is not guaranteed

EURACTIV - Over the next decade, a wave of biologic medicines will lose patent protection in Europe, but unlike the past ten years, biosimilar competition and the savings and access it brought are no longer guaranteed to follow. Read more

[Getty Images: mego.picturae]